Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 15623647)

  • 1. Mouse homologue of a novel human oncofetal antigen, glypican-3, evokes T-cell-mediated tumor rejection without autoimmune reactions in mice.
    Nakatsura T; Komori H; Kubo T; Yoshitake Y; Senju S; Katagiri T; Furukawa Y; Ogawa M; Nakamura Y; Nishimura Y
    Clin Cancer Res; 2004 Dec; 10(24):8630-40. PubMed ID: 15623647
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of HLA-A2- or HLA-A24-restricted CTL epitopes possibly useful for glypican-3-specific immunotherapy of hepatocellular carcinoma.
    Komori H; Nakatsura T; Senju S; Yoshitake Y; Motomura Y; Ikuta Y; Fukuma D; Yokomine K; Harao M; Beppu T; Matsui M; Torigoe T; Sato N; Baba H; Nishimura Y
    Clin Cancer Res; 2006 May; 12(9):2689-97. PubMed ID: 16675560
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Embryonic stem cell-derived dendritic cells expressing glypican-3, a recently identified oncofetal antigen, induce protective immunity against highly metastatic mouse melanoma, B16-F10.
    Motomura Y; Senju S; Nakatsura T; Matsuyoshi H; Hirata S; Monji M; Komori H; Fukuma D; Baba H; Nishimura Y
    Cancer Res; 2006 Feb; 66(4):2414-22. PubMed ID: 16489048
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DNA vaccination of HSP105 leads to tumor rejection of colorectal cancer and melanoma in mice through activation of both CD4 T cells and CD8 T cells.
    Miyazaki M; Nakatsura T; Yokomine K; Senju S; Monji M; Hosaka S; Komori H; Yoshitake Y; Motomura Y; Minohara M; Kubo T; Ishihara K; Hatayama T; Ogawa M; Nishimura Y
    Cancer Sci; 2005 Oct; 96(10):695-705. PubMed ID: 16232202
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of a novel tumor-associated antigen, cadherin 3/P-cadherin, as a possible target for immunotherapy of pancreatic, gastric, and colorectal cancers.
    Imai K; Hirata S; Irie A; Senju S; Ikuta Y; Yokomine K; Harao M; Inoue M; Tsunoda T; Nakatsuru S; Nakagawa H; Nakamura Y; Baba H; Nishimura Y
    Clin Cancer Res; 2008 Oct; 14(20):6487-95. PubMed ID: 18927288
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of the H2-Kd-restricted cytotoxic T lymphocyte epitopes of a tumor-associated antigen, SPARC, which can stimulate antitumor immunity without causing autoimmune disease in mice.
    Ikuta Y; Hayashida Y; Hirata S; Irie A; Senju S; Kubo T; Nakatsura T; Monji M; Sasaki Y; Baba H; Nishimura Y
    Cancer Sci; 2009 Jan; 100(1):132-7. PubMed ID: 19068096
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HLA-A2 and -A24-restricted glypican-3-derived peptide vaccine induces specific CTLs: preclinical study using mice.
    Motomura Y; Ikuta Y; Kuronuma T; Komori H; Ito M; Tsuchihara M; Tsunoda Y; Shirakawa H; Baba H; Nishimura Y; Kinoshita T; Nakatsura T
    Int J Oncol; 2008 May; 32(5):985-90. PubMed ID: 18425324
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glypican-3 could be an effective target for immunotherapy combined with chemotherapy against ovarian clear cell carcinoma.
    Suzuki S; Yoshikawa T; Hirosawa T; Shibata K; Kikkawa F; Akatsuka Y; Nakatsura T
    Cancer Sci; 2011 Sep; 102(9):1622-9. PubMed ID: 21668581
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Ad hTRP2 - mediated immunity against melanoma is enhanced by dendritic cells pulsed with peptide].
    Tan XH; Liu C; Wan YH
    Zhonghua Zhong Liu Za Zhi; 2006 Sep; 28(9):658-61. PubMed ID: 17274369
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Usefulness of a novel oncofetal antigen, glypican-3, for diagnosis and immunotherapy of hepatocellular carcinoma].
    Nishimura Y; Nakatsura T; Senju S
    Nihon Rinsho Meneki Gakkai Kaishi; 2008 Oct; 31(5):383-91. PubMed ID: 18974622
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HLA-A2-restricted glypican-3 peptide-specific CTL clones induced by peptide vaccine show high avidity and antigen-specific killing activity against tumor cells.
    Yoshikawa T; Nakatsugawa M; Suzuki S; Shirakawa H; Nobuoka D; Sakemura N; Motomura Y; Tanaka Y; Hayashi S; Nakatsura T
    Cancer Sci; 2011 May; 102(5):918-25. PubMed ID: 21281401
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antitumor effects of systemic and local immunization with a CTL-directed peptide in combination with a local injection of OK-432.
    Ono T; Harada M; Yamada A; Tanaka M; Takao Y; Tanaka Y; Mine T; Sakamoto K; Nakashima T; Itoh K
    Clin Cancer Res; 2006 Feb; 12(4):1325-32. PubMed ID: 16489090
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction of CD4(+) and CD8(+) T-cell responses to the human stromal antigen, fibroblast activation protein: implication for cancer immunotherapy.
    Fassnacht M; Lee J; Milazzo C; Boczkowski D; Su Z; Nair S; Gilboa E
    Clin Cancer Res; 2005 Aug; 11(15):5566-71. PubMed ID: 16061874
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The cytotoxic T-lymphocyte response against a poorly immunogenic mammary adenocarcinoma is focused on a single immunodominant class I epitope derived from the gp70 Env product of an endogenous retrovirus.
    Rosato A; Dalla Santa S; Zoso A; Giacomelli S; Milan G; Macino B; Tosello V; Dellabona P; Lollini PL; De Giovanni C; Zanovello P
    Cancer Res; 2003 May; 63(9):2158-63. PubMed ID: 12727834
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Definition of an immunogenic region within the ovarian tumor antigen stratum corneum chymotryptic enzyme.
    Bondurant KL; Crew MD; Santin AD; O'Brien TJ; Cannon MJ
    Clin Cancer Res; 2005 May; 11(9):3446-54. PubMed ID: 15867247
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radiofrequency ablation for hepatocellular carcinoma induces glypican-3 peptide-specific cytotoxic T lymphocytes.
    Nobuoka D; Motomura Y; Shirakawa H; Yoshikawa T; Kuronuma T; Takahashi M; Nakachi K; Ishii H; Furuse J; Gotohda N; Takahashi S; Nakagohri T; Konishi M; Kinoshita T; Komori H; Baba H; Fujiwara T; Nakatsura T
    Int J Oncol; 2012 Jan; 40(1):63-70. PubMed ID: 21922136
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
    Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
    Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of glypican-3 as a novel tumor marker for melanoma.
    Nakatsura T; Kageshita T; Ito S; Wakamatsu K; Monji M; Ikuta Y; Senju S; Ono T; Nishimura Y
    Clin Cancer Res; 2004 Oct; 10(19):6612-21. PubMed ID: 15475451
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor immunotherapy targeting fibroblast activation protein, a product expressed in tumor-associated fibroblasts.
    Lee J; Fassnacht M; Nair S; Boczkowski D; Gilboa E
    Cancer Res; 2005 Dec; 65(23):11156-63. PubMed ID: 16322266
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapy of established tumors in a novel murine model transgenic for human carcinoembryonic antigen and HLA-A2 with a combination of anti-idiotype vaccine and CTL peptides of carcinoembryonic antigen.
    Saha A; Chatterjee SK; Foon KA; Celis E; Bhattacharya-Chatterjee M
    Cancer Res; 2007 Mar; 67(6):2881-92. PubMed ID: 17363612
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.